Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.

ABSTRACT:

Importance

Both tacrolimus (TAC) and mycophenolate mofetil (MMF) are recommended for children with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). However, their comparative effectiveness and safety have not been evaluated through randomized clinical trials.

Objective

To compare the effectiveness and safety of TAC and MMF in children with FRNS or SDNS.

Design, setting, and participants

In this multicenter, open-label randomized clinical trial conducted at 12 pediatric nephrology centers across China, 270 children aged 2 to 18 years with FRNS or SDNS were allocated at a 1:1 ratio to treatment with either TAC or MMF. The study was conducted from November 2019 to July 2023, and data analysis was completed from July 2023 to M

SUBMITTER: Wang J 

PROVIDER: S-EPMC12070277 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature